Safety
GLP-1 Side Effects: What Happens, and When
Medically reviewed by Dr. J. Adam, MD · Updated July 23, 2026 · Sources cited below
Gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — are the most common adverse events and they are change-driven rather than dose-driven. They concentrate at initiation and in the days after each escalation, and commonly settle as exposure stabilises. Serious risks in labelling include pancreatitis, gallbladder disease and a boxed warning on thyroid C-cell tumours.
Key takeaways
- Gastrointestinal effects cluster after each dose change, not evenly across treatment.
- Most are mild to moderate, but they are the leading reason people discontinue.
- Constipation frequently outlasts nausea because two mechanisms sustain it.
- Severe abdominal pain radiating to the back with persistent vomiting needs urgent assessment.
- In SURMOUNT-5, GI discontinuation was 2.7% for tirzepatide against 5.6% for semaglutide.
| Most common | Nausea, diarrhoea, vomiting, constipation |
|---|---|
| Timing | Concentrated at initiation and after each escalation |
| Typical severity | Mild to moderate |
| Boxed warning | Thyroid C-cell tumours observed in rodents |
| Serious risks in labelling | Pancreatitis, gallbladder disease, hypersensitivity |
| GI discontinuation (SURMOUNT-5) | 2.7% tirzepatide vs 5.6% semaglutide |
Why the timing pattern matters more than the list
Almost every side-effect page lists the same symptoms. Far more useful is knowing when they arrive, because that is what makes them predictable and manageable.
The mechanism is change-driven. Slowed gastric emptying and central appetite signalling respond to a shift in exposure rather than to exposure itself. Step up a dose and the system encounters a new level; symptoms appear or intensify, then commonly settle as it stabilises.
This explains a pattern people find confusing: someone comfortable at 10 mg can feel distinctly unwell for several days after moving to 12.5 mg, then return to comfort. The system is adapting, not failing.
| Effect | When it peaks | Typical course | When to escalate |
|---|---|---|---|
| Nausea | Initiation and each dose step | Commonly settles as exposure stabilises | Severe pain radiating to the back |
| Diarrhoea | Escalation windows | Usually transient | Blood, fever, or dehydration signs |
| Vomiting | Escalation windows | Usually transient | Persistent, preventing fluid intake |
| Constipation | Builds over weeks | Frequently persists | No stool or gas with pain or distension |
| Injection-site reaction | Any time | Mild and short-lived | Spreading, warm, or febrile |
What to expect in the first months
The starting dose is a tolerance-building dose rather than a treatment dose, and the first weeks are spent below the exposures that produced trial results. Many people notice appetite change quickly while weight moves slowly, which is the expected sequence rather than a sign of failure.
Each escalation restarts the adaptation window. Planning around that helps: a dose step before a week of demanding commitments or travel is worth avoiding if the schedule allows flexibility, which is a conversation to have with a prescriber.
Once a maintenance dose is reached and exposure stops changing, gastrointestinal effects generally settle substantially. Someone who tolerated escalation is unlikely to encounter a sudden new problem at a stable dose.
Why constipation behaves differently
Nausea usually resolves and constipation frequently does not, which people find discouraging until they understand why. Two mechanisms sustain constipation and only one fades.
Slowed gastrointestinal transit is a direct drug effect that partial tolerance addresses. But reduced food volume and reduced fluid intake are consequences of the appetite suppression that is the therapeutic goal — and those persist for as long as the treatment is working.
That makes constipation a management problem rather than an adaptation problem. It is worth raising with a prescriber or pharmacist, not because it is dangerous but because it is treatable, and untreated it is a common reason people abandon treatment that was otherwise succeeding.
The symptoms that are not routine
Severe abdominal pain, particularly persistent rather than fluctuating and radiating from the upper abdomen through to the back, can indicate pancreatitis and requires urgent assessment. The specific danger is attribution error: patients have been told to expect abdominal discomfort, so they wait.
Persistent vomiting or diarrhoea preventing fluid intake is a separate concern because of dehydration, which matters more in older adults and in anyone taking diuretics, ACE inhibitors, ARBs or NSAIDs. Confusion and reduced urine output are under-recognised signs.
A new neck lump, hoarseness or difficulty swallowing should be reported promptly given the boxed warning. Swelling of the face, lips or throat, or breathing difficulty, is an emergency.
Do the two main drugs differ?
In SURMOUNT-5, the only head-to-head randomised comparison, discontinuation from gastrointestinal effects was 2.7% with tirzepatide against 5.6% with semaglutide. Both produced gastrointestinal effects in most participants at some point; the difference was in how often those effects ended treatment.
That is a genuinely useful number because it measures consequence rather than incidence. Everyone reports some nausea; what matters is how often it becomes intolerable.
One caveat: the trial was open-label, and discontinuation decisions involve judgement on both sides. The weight endpoints are less exposed to that limitation than the discontinuation figures are.
View chart data as a table
| Group | Tirzepatide | Semaglutide |
|---|---|---|
| Discontinued for GI effects | 2.7% | 5.6% |
Frequently asked questions
What are the most common GLP-1 side effects?
Nausea, diarrhoea, vomiting and constipation — mostly mild to moderate and concentrated around dose changes.
Do they go away?
They commonly settle as exposure stabilises at a given dose, though constipation frequently persists longer.
Why does constipation last longer?
Slowed transit is a direct drug effect, but reduced food and fluid intake independently contribute and persist while treatment works.
When should I seek urgent care?
Severe abdominal pain radiating to the back with persistent vomiting, signs of serious allergic reaction, or a new neck lump with hoarseness.
Is one drug better tolerated?
In SURMOUNT-5, GI discontinuation was 2.7% with tirzepatide against 5.6% with semaglutide.
Sources
Every clinical claim above links to a primary source: an FDA record, a peer-reviewed publication with DOI or PMID, or a ClinicalTrials.gov registration. Where a figure could not be verified against a primary source, it is labelled rather than asserted.
rel="nofollow noopener". Rankings follow our
published methodology. See conflicts
of interest. This article is information, not medical advice.